title: Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study.
authors.forename: Justin
authors.initials: J
authors.lastname: Stebbing
authors.forename: Laura
authors.initials: L
authors.lastname: Waters
authors.forename: Liz
authors.initials: L
authors.lastname: Davies
authors.forename: Sundhiya
authors.initials: S
authors.lastname: Mandalia
authors.forename: Mark
authors.initials: M
authors.lastname: Nelson
authors.forename: Brian
authors.initials: B
authors.lastname: Gazzard
authors.forename: Mark
authors.initials: M
authors.lastname: Bower
mesh_terms: D053961:Azabicyclo Compounds; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D015497:HIV-1 / Q000472:pathogenicity*; D006801:Humans; D015994:Incidence; D008297:Male; D009369:Neoplasms / Q000139:chemically induced* / Q000188:drug therapy; D010879:Piperazines / Q000009:adverse effects*
chemical_list: D053961:Azabicyclo Compounds; D010879:Piperazines; C515050:zopiclone